Jpmorgan Chase & CO Anebulo Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 9 shares of ANEB stock, worth $13. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9
Previous 10
10.0%
Holding current value
$13
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ANEB
# of Institutions
14Shares Held
7.34MCall Options Held
0Put Options Held
0-
22 Nw, LP Seattle, WA5.37MShares$7.83 Million11.7% of portfolio
-
Lvw Advisors, LLC641KShares$935,9160.16% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT511KShares$746,1660.06% of portfolio
-
Morgan Stanley New York, NY399KShares$582,8590.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX158KShares$230,4780.05% of portfolio
About Anebulo Pharmaceuticals, Inc.
- Ticker ANEB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,633,200
- Market Cap $37.4M
- Description
- Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...